Navigation Links
Enhanze in Medical News

Halozyme Therapeutics to Hold Pipeline Update Conference Call on August 8

...nology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therape...

Halozyme Therapeutics Added to Nasdaq Biotech Index

...covering the family of human enzymes known as hyaluronidases. The company's enhanze Technology is a novel drug delivery platform designed to increase the absor...logical therapeutic compounds for up to 13 targets and with Baxter to apply enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID 10...

Baxter Reports Strong Third Quarter Sales and Earnings

...wn as KIOVIG(TM) in Europe). For patients using GAMMAGARD LIQUID 10% - currently administered intravenously - subcutaneous administration with enhanze Technology may increase convenience and improve the dispersion of the therapy. -- A collaboration with DEKA Research & Development Corp. and HHD...
Enhanze in Medical Technology

Halozyme Therapeutics' Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society

- Co-Injection of rHuPH20 with Humira Estimated to Increase the Maximal Steady State Subcutaneous Bioavailability from 64% to 100% - SAN DIEGO, July 09, 2007 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. , a biopharmaceutical company developing and commercializing recombinant human enzymes...

Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme

...an enzymes known as hyaluronidases. The company's enhanze Technology is a novel drug delivery platform desig...ics. Its key partnerships are with Roche to apply enhanze Technology to Roche's biological therapeutic compo...unds for up to 13 targets and with Baxter to apply enhanze Technology to Baxter's biological therapeutic comp...

Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target

...hase 1 pharmacokinetic clinical trial with a subcutaneous formulation using enhanze Technology of a biologic directed to a Roche exclusive target. This has tri...logical therapeutic compounds for up to 13 targets and with Baxter to apply enhanze Technology to Baxter's biological therapeutic product, GAMMAGARD LIQUID 10%...

Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models

...nology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therape...

Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial

...nology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therape...

Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability

...nology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therape...

Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference

... key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cum...

Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference

... key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cum...

Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously

... Phase I/II data showed that enhanze Technology(TM) enabled subcutaneous administrat... administered combination of GAMMAGARD LIQUID with enhanze Technology was 92 percent of the traditional, mont...ivotal Phase III trial using GAMMAGARD LIQUID with enhanze Technology pending discussions with regulatory aut...

Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex

... key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cum...
Enhanze in Biological Technology

Halozyme Receives $5.5 Million Payment From Baxter

...s that affect the extracellular matrix. Halozyme's enhanze Technology is a novel drug delivery platform desi...e company has key partnerships with Roche to apply enhanze Technology to Roche's biological therapeutic compo... to 13 targets and with Baxter BioScience to apply enhanze Technology to Baxter's biological therapeutic comp...

Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients

...neous (SC) administration of GAMMAGARD LIQUID with enhanze Technology is an investigational study and when ap...gics. Its key partnerships are with Roche to apply enhanze Technology to Roche's biological therapeutic compo...unds for up to 13 targets and with Baxter to apply enhanze Technology to Baxter's biological therapeutic comp...

Halozyme Therapeutics Reports 2008 Third Quarter Financial Results

...n and dispersion of biologics. Its key partnerships are with Roche to apply enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply enhanze Technology to Baxter's biological therapeutic product, GAMMAGARD LIQUID 10%...

Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients

...nology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therape...

Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results

...nology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therape...

Halozyme Therapeutics to Present at Upcoming Investor Conferences

...nology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therape...

Halozyme Therapeutics to Host Research Day for Investors and Analysts

...nology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therape...

Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development

...nology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therape...

Halozyme Therapeutics to Present at Upcoming Investor Conferences

...nology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therape...

Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives

...nology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therape...
Other Tags
(Date:5/27/2015)... The Case Management Society of ... provide CMSA's Career and Knowledge Pathways educational program ... strengthen the case/care management workforce by offering aptitude ... mutually beneficial agreement provides Medix, a workforce solutions ... in the healthcare, scientific and IT industries, access ...
(Date:5/27/2015)... CompanionDx announced that its ... analysis in personalized cancer therapy: Non-small cell lung cancer ... of Clinical Oncology (ASCO) as part of their annual ... The molecular and clinical data used for the study ... The study reports improved patient outcomes from a preliminary ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 This ... current state of the Omega-3 industry. The report ... definitions, classifications, applications and industry chain structure. The ... markets including development trends, competitive landscape analysis, and ... Rieber Oils, Camanchaca Fishing Company, Seadragon Marine Oils, ...
(Date:5/27/2015)... “Heroin has never been more plentiful or cheaper, ... from,” says Harford County Sheriff Jeff Gahler, as quoted by ... surging heroin related incidents in Baltimore, police resources are running ... heroin addiction and subsequent abuse before it turns into a ... is a drug and alcohol rehab facility specializing in heroin ...
(Date:5/27/2015)... May 27, 2015 A television program ... MediaSource and Roswell Park Cancer Institute ... The award-winning story, Cancer Can’t Win , highlights ... Park Cancer Institute. The production team followed five people ... months as they received treatment from doctors and medical ...
Breaking Medicine News(10 mins):Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 3Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 2Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 3Health News:Omega-3 Market: Global 2015 Analysis & 2020 Forecasts on Market Size 2Health News:The Price of Heroin in Baltimore Drops, Surging Use and Causing Rife Overdose Deaths 2Health News:The Price of Heroin in Baltimore Drops, Surging Use and Causing Rife Overdose Deaths 3Health News:MediaSource Wins New York Emmy® Award as Premier Health Care Storytellers 2Health News:MediaSource Wins New York Emmy® Award as Premier Health Care Storytellers 3
(Date:4/20/2015)... 2015 The announcement comes as ... Records Management (GRM), Ireland,s foremost records ... Having built up an impressive track record of clients within ... within the records management sector in Dubai ... GCC staffbase and employ a further eight staff members at ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/13/2015)... 2015 According to a ... Market Forecast & Opportunities, 2020", the global biometrics market ... 14% till 2020. The biometrics market is garnering ... and review of biometric management systems. The constant ... with greater efficiency, are resulting in increasing installation ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
Other Contents